Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Start a request for Inpegsomatropin on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
China
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Inpegsomatropin is a once-a-week growth hormone injection for children who are not growing properly because their body makes too little growth hormone. It was developed and is made in China by Xiamen Amoytop Biotech, where it is sold as 益佩生® (Yipeisheng). Instead of the daily injections many children need, it is given just once a week.
China's National Medical Products Administration (NMPA) approved it in May 2025 for:
It is a prescription hormone medicine and should only be used under a paediatric endocrinologist.
Growth hormone is made by the pituitary gland at the base of the brain and drives the growth of bones and muscles, mostly through a second messenger called IGF-1. Inpegsomatropin is lab-made human growth hormone with a large, Y-shaped (branched) 40 kD polyethylene glycol (PEG) chain attached to it. This "PEG coat" slows down how fast the body clears the hormone, so one injection keeps working for a whole week. The company says it is the first Y-shaped PEG growth hormone approved anywhere.
The phase 3 trial, published in The Journal of Clinical Endocrinology & Metabolism, included 391 children aged about 3 to 11 years at 23 centres in China. Two in three received weekly inpegsomatropin, and one in three received standard daily growth hormone injections, for 52 weeks. Children on the weekly injection grew an average of 9.91 cm in the year, compared with 10.04 cm on daily injections (before treatment they were growing about 3.5 cm a year). This showed the weekly medicine works as well as daily treatment, using a lower total weekly dose and with 52 injections a year instead of about 365.
As an example, a 20 kg child would need about 2.8 mg a week. It comes as a ready-to-use clear liquid in prefilled cartridges of 2.5 mg, 3.0 mg, 3.5 mg and 5.0 mg, or a 2.0 mg vial. Your doctor sets the exact dose.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Who should not use it: children allergic to inpegsomatropin or any ingredient, children whose growth plates have already closed, anyone with an active or growing tumour, and people who are critically ill after open-heart or abdominal surgery, multiple injuries or sudden breathing failure.
Side effects in the trial: no very common (10% or more) side effects linked to the medicine were reported. The most frequent were injection site reactions (9.6%), raised liver enzymes ALT and AST (1.1% each), joint pain (1.1%), raised TSH (0.8%), rash (0.8%) and eyelid swelling (0.8%). Serious events were similar with weekly and daily treatment (6.5% vs 6.2%), only 1.5% stopped in each group, and no child on inpegsomatropin developed new antibodies against it.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant, cold-chain conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
The injection can be imported only in the patient's name, by the patient or a government hospital, in line with India's import regulations for unapproved medicines. You will need:
Once we have received and checked a valid prescription and, where needed, an import permit.
No. It is approved only in China. It has no CDSCO approval, it is not sold in Indian pharmacies, and the US FDA and European Medicines Agency have not approved it either.
Patients can still get it legally through the Named Patient Program (NPP), which allows a medicine not registered in India to be imported for one specific patient on a prescription. Your child's endocrinologist may also want to read about Ngenla, another once-weekly growth hormone that we import on prescription.
It can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.
NamedPatientProgram.com (NPP) sources this medicine through the manufacturer's authorised supply channels in China and arranges supply to patients, doctors, and hospitals under applicable legal provisions. The cartridges and vials must be kept at 2°C to 8°C, away from light, and must not be frozen or shaken hard, so they travel under temperature-controlled shipping from the source to your door or clinic. Because the dose is based on weight and changes as the child grows, we plan each order around the current prescription. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.
For the current cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.
Families across India can access this medicine through regulated import pathways, with cold-chain delivery arranged to the home or treating hospital on a valid specialist's prescription.
Paediatric endocrine clinics in Delhi see children from across North India, and our New Delhi dispatch point keeps the cold-chain journey short.
Parents in Mumbai can have the refrigerated cartridges delivered to their home or to the child's clinic.
Paediatric endocrinologists in Bangalore can request the medicine for a named child, with a written quote shared first.
Doctors in Chennai can send us the growth chart and test reports to begin the import.
We plan deliveries so a fresh supply arrives before the last weekly dose is used.
Shipments to Kolkata and the eastern states are packed to stay between 2°C and 8°C all the way.
Families in Pune can use the same documented import route, with updates at every stage.
The treating doctor can share the prescription and bone age report with us to start the import.
Serves families from Punjab, Haryana and Himachal Pradesh, with delivery to the home or treating hospital.
Families across Rajasthan can receive the medicine without travelling, as long as the import is in the child's name.
We coordinate cold-chain delivery to families and children's hospitals across Uttar Pradesh.
Families in Kochi and nearby Kerala cities can have each supply delivered in insulated packaging.
Access can also be coordinated for patients in other Indian cities, subject to a valid prescription and regulatory requirements.
Written By
Nitin GoswamiDeputy Manager – Content & Social Media, Ikris Pharma Network
Sources: NMPA • CDSCO
Last Updated: 19 October 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
